fbpx
Medical Innovation Exchange

Vivoryon’s stock climbs as midphase Alzheimer’s disease trial determines optimal dose

https://www.fiercebiotech.com/biotech/vivoryons-stock-climbs-midphase-alzheimers-disease-trial-determines-optimal-dose

Leave a Comment

Your email address will not be published.

Leave the field below empty!

This site uses Akismet to reduce spam. Learn how your comment data is processed.